87.12
price up icon0.79%   0.68
after-market アフターアワーズ: 91.47 4.35 +4.99%
loading
前日終値:
$86.44
開ける:
$80.22
24時間の取引高:
2.33M
Relative Volume:
4.66
時価総額:
$4.65B
収益:
$144.75M
当期純損益:
$-53.89M
株価収益率:
-22.00
EPS:
-3.96
ネットキャッシュフロー:
$-42.88M
1週間 パフォーマンス:
-0.15%
1か月 パフォーマンス:
+11.36%
6か月 パフォーマンス:
+65.34%
1年 パフォーマンス:
+95.21%
1日の値動き範囲:
Value
$77.00
$87.74
1週間の範囲:
Value
$77.00
$91.20
52週間の値動き範囲:
Value
$43.50
$97.54

Arcellx Inc Stock (ACLX) Company Profile

Name
名前
Arcellx Inc
Name
セクター
Healthcare (1182)
Name
電話
240-327-0603
Name
住所
800 BRIDGE PARKWAY, REDWOOD CITY
Name
職員
130
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
ACLX's Discussions on Twitter

Arcellx Inc Stock (ACLX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-01-04 繰り返されました Needham Buy
2023-12-19 開始されました Scotiabank Sector Outperform
2023-10-30 開始されました TD Cowen Outperform
2023-10-17 開始されました UBS Buy
2023-05-18 開始されました Truist Buy
2023-04-14 開始されました Robert W. Baird Outperform
2023-03-14 開始されました Stifel Buy
2023-02-13 開始されました H.C. Wainwright Buy
2022-12-13 再開されました BofA Securities Buy
2022-10-31 開始されました Guggenheim Buy
2022-10-27 開始されました Needham Buy
2022-07-20 開始されました Canaccord Genuity Buy
2022-03-01 開始されました BofA Securities Buy
2022-03-01 開始されました SVB Leerink Outperform
すべてを表示

Arcellx Inc (ACLX) 最新ニュース

pulisher
03:28 AM

BofA raises Arcellx price target to $100 on positive data - Investing.com

03:28 AM
pulisher
02:36 AM

Arcellx (NASDAQ:ACLX) Shares Gap DownHere's Why - MarketBeat

02:36 AM
pulisher
09:53 AM

Arcellx issues updates on anito-cel clinical trials (NASDAQ:ACLX) - Seeking Alpha

09:53 AM
pulisher
09:50 AM

Mirae Asset Global Investments Co. Ltd. Acquires 347 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World

09:50 AM
pulisher
09:35 AM

Arcellx : to Present Clinical Data for Its Phase 1 and iMMagine 1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine 3 Study Form 8 K - Marketscreener.com

09:35 AM
pulisher
09:20 AM

Arcellx reports promising results for myeloma treatment - Investing.com

09:20 AM
pulisher
09:17 AM

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study - Marketscreener.com

09:17 AM
pulisher
09:00 AM

Arcellx's Multiple Myeloma Drug Shows 95% Response Rate in Phase 2 Trial, Strong Safety Data | ACLX Stock News - StockTitan

09:00 AM
pulisher
07:19 AM

Cancer cell therapy from Arcellx, Gilead shows promise in early data - Yahoo Finance

07:19 AM
pulisher
05:22 AM

Arcellx, Inc. (NASDAQ:ACLX) Shares Purchased by Harbor Capital Advisors Inc. - MarketBeat

05:22 AM
pulisher
Nov 04, 2024

abrdn plc Takes Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat

Nov 02, 2024
pulisher
Nov 02, 2024

Arcellx (NASDAQ:ACLX) Earns “Buy” Rating from Needham & Company LLC - Defense World

Nov 02, 2024
pulisher
Oct 31, 2024

Arcellx (ACLX) Surged in Q3. Here’s Why - Insider Monkey

Oct 31, 2024
pulisher
Oct 31, 2024

Arcellx (NASDAQ:ACLX) Receives Buy Rating from Needham & Company LLC - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 5.3% - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Increases By 5.3% - Defense World

Oct 31, 2024
pulisher
Oct 29, 2024

Arcellx shares target increased, Outperform upheld as ASH data release nears - Investing.com India

Oct 29, 2024
pulisher
Oct 28, 2024

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX) - Simply Wall St

Oct 28, 2024
pulisher
Oct 24, 2024

Arcellx's SWOT analysis: cell therapy innovator's stock poised for growth By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 24, 2024

Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores - STAT

Oct 24, 2024
pulisher
Oct 23, 2024

Arcellx's SWOT analysis: cell therapy innovator's stock poised for growth - Investing.com India

Oct 23, 2024
pulisher
Oct 22, 2024

Arcellx director Kavita Patel sells $134,535 in stock - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Arcellx, Inc. (NASDAQ:ACLX) Director Sells $134,535.00 in Stock - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Arcellx director Kavita Patel sells $134,535 in stock By Investing.com - Investing.com Canada

Oct 22, 2024
pulisher
Oct 22, 2024

Cracking The Code: Understanding Analyst Reviews For Arcellx - Benzinga

Oct 22, 2024
pulisher
Oct 22, 2024

Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Buy" from Analysts - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Arcellx (NASDAQ:ACLX) Reaches New 52-Week High After Analyst Upgrade - Defense World

Oct 22, 2024
pulisher
Oct 21, 2024

Arcellx (NASDAQ:ACLX) Reaches New 12-Month High After Analyst Upgrade - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Canaccord Genuity Group Increases Arcellx (NASDAQ:ACLX) Price Target to $115.00 - Defense World

Oct 21, 2024
pulisher
Oct 20, 2024

Stifel Nicolaus Increases Arcellx (NASDAQ:ACLX) Price Target to $122.00 - Defense World

Oct 20, 2024
pulisher
Oct 19, 2024

(ACLX) Trading Advice - Stock Traders Daily

Oct 19, 2024
pulisher
Oct 18, 2024

Stifel lifts Arcellx stock target, keeps buy rating on safety profile optimism - Investing.com India

Oct 18, 2024
pulisher
Oct 18, 2024

4 Analysts Assess Arcellx: What You Need To Know - Benzinga

Oct 18, 2024
pulisher
Oct 18, 2024

Arcellx (NASDAQ:ACLX) PT Raised to $122.00 - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Stifel lifts Arcellx stock target, keeps buy rating on safety profile optimism By Investing.com - Investing.com South Africa

Oct 18, 2024
pulisher
Oct 17, 2024

Arcellx (NASDAQ:ACLX) PT Raised to $115.00 at Canaccord Genuity Group - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Arcellx stock soars to all-time high of $88.67 amid robust growth - Investing.com Australia

Oct 17, 2024
pulisher
Oct 16, 2024

Examining the Potential Price Growth of Arcellx Inc (ACLX) - Knox Daily

Oct 16, 2024
pulisher
Oct 15, 2024

Arcellx (NASDAQ:ACLX) Reaches New 1-Year HighTime to Buy? - MarketBeat

Oct 15, 2024
pulisher
Oct 13, 2024

Arcellx, Inc. (NASDAQ:ACLX) Shares Acquired by AQR Capital Management LLC - Defense World

Oct 13, 2024
pulisher
Oct 11, 2024

12,035 Shares in Arcellx, Inc. (NASDAQ:ACLX) Purchased by SG Americas Securities LLC - MarketBeat

Oct 11, 2024
pulisher
Oct 09, 2024

Arcellx Inc (ACLX) may enjoy gains as insiders got busy in the recent days - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

ACLX’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

(ACLX) Technical Data - Stock Traders Daily

Oct 08, 2024
pulisher
Oct 08, 2024

Arcellx (NASDAQ:ACLX) Shares Gap UpHere's What Happened - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Redburn sees Arcellx stock gaining from innovative CAR-T platform and strong growth - Investing.com Canada

Oct 08, 2024
pulisher
Oct 08, 2024

The Manufacturers Life Insurance Company Increases Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World

Oct 08, 2024
pulisher
Oct 08, 2024

Arcellx (NASDAQ:ACLX) Earns Buy Rating from Analysts at Redburn Atlantic - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

The Manufacturers Life Insurance Company Boosts Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat

Oct 08, 2024

Arcellx Inc (ACLX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):